EUVIMEDEUVIMED entdecken
Open Access

Single coadministration of erythrocyte-uricase conjugate and immunosuppressant induces durable immune tolerance for gout therapy

Xiaoqian Nie iD, Yuehua Liu iD, Xingyun Yao iD, Chaohao Wu iD, Xiaofei Gao iD

Science Advances · 2025

DOI: 10.1126/sciadv.aea5196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Xiaoqian Nie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Industries of the Future and School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310030, China. Hauptthemen laut MEDLINE: Urate Oxidase, Immunosuppressive Agents, Immune Tolerance, Gout. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Key R&D Program of Zhejiang.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uricase (UOX) is effective for treating refractory gout but is limited by antidrug antibody (ADA) formation, which leads to loss of efficacy and infusion reactions. Here, we demonstrate that a single coadministration of erythrocyte-conjugated UOX (UOX-Ery) with an immunosuppressant such as cyclophosphamide (CTX) induces robust and durable antigen-specific immune tolerance. This one-time intervention effectively prevented ADA formation in mice and rats, even after repeated challenges with UOX-Ery or free UOX protein, an outcome not achieved by CTX or UOX plus CTX. This tolerogenic effect relied on splenic uptake of UOX-Ery by myeloid cells, particularly macrophages, and was associated with the expansion of a distinct subset of effector regulatory T cells. Functionally, this immune tolerance enhanced the pharmacokinetics of UOX, sustained long-term control of serum uric acid levels, and attenuated local inflammation within tophus-like lesions. Together, these findings demonstrate that UOX-Ery, combined in a single dose with clinically used immunosuppressants, can effectively treat gout by inducing antigen-specific immune tolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urate OxidaseImmunosuppressive AgentsImmune ToleranceGoutErythrocytesAnimalsMiceRatsMaleCyclophosphamideUric AcidHumansT-Lymphocytes, RegulatoryDisease Models, Animal

Substanzen

Urate OxidaseImmunosuppressive AgentsCyclophosphamideUric Acid

Autor:innen und Institutionen

  • Research Center for Industries of the Future and School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310030, China.
  • Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang 310024, China.
  • Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310030, China.

ORCID-Profile: Xiaoqian Nie, Yuehua Liu, Xingyun Yao, Chaohao Wu, Xiaofei Gao

Förderung

  • Key R&D Program of Zhejiang

Zitieren

APA

Nie, X., Liu, Y., Yao, X., Wu, C., & Gao, X. (2025). Single coadministration of erythrocyte-uricase conjugate and immunosuppressant induces durable immune tolerance for gout therapy. Science Advances. https://doi.org/10.1126/sciadv.aea5196

Vancouver

Nie X, Liu Y, Yao X, Wu C, Gao X. Single coadministration of erythrocyte-uricase conjugate and immunosuppressant induces durable immune tolerance for gout therapy. Science Advances. 2025. doi:10.1126/sciadv.aea5196

BibTeX
@article{Nie2025,
  author = {Nie, Xiaoqian and Liu, Yuehua and Yao, Xingyun and Wu, Chaohao and Gao, Xiaofei},
  title = {Single coadministration of erythrocyte-uricase conjugate and immunosuppressant induces durable immune tolerance for gout therapy},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.aea5196}
}
Kostenlos starten →